Catie.ca. We are profoundly grateful for your dedication to helping patients and communities affected by COVID-19. Tenofovir Alafenamide. “This approval provides more prevention options for certain patients at-risk for acquiring HIV and helps further efforts by the FDA and the U.S. Department of Health and Human Services to facilitate the development of HIV treatment and prevention options to reduce new HIV infections.”According to the Centers for Disease Control and Prevention, 38,739 people received an HIV diagnosis in the U.S. in 2017. The most common adverse reaction in individuals without HIV who were taking Descovy for PrEP was diarrhea.There is a boxed warning for individuals who take Descovy who also have hepatitis B virus (HBV) to be aware of the risk of exacerbations of HBV in those who discontinue products with emtricitabine or tenofovir disproxil fumarate, and which may occur in individuals who discontinue Descovy. Descovy was first approved in April 2016 in combination with other antiretoviral drugs to Descovy for PrEP is indicated for use in at-risk, adult and adolescent HIV-negative men and transgender women (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.Descovy is the second medicine to be FDA approved for PrEP, after the approval of The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. FDA approved Descovy in at-risk adults and adolescents for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex because the effectiveness in this population has not been evaluated.“PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent HIV infection,” said Jeffrey Murray, M.D., M.P.H., deputy director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research. We have adequate supply of our products and do not foresee any threat to our supply chain for the foreseeable future. DESCOVY ® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. Details on the drug. DESCOVY, the DESCOVY Logo, DESCOVY FOR PrEP, the DESCOVY FOR PrEP Logo, the DESCOVY Blue Pill Design, DAYTRACKER, TRUVADA, the TRUVADA Blue Pill Design, ADVANCING ACCESS, GSI, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. This information is intended for US Healthcare Professionals.The long-term clinical significance of changes in eGFR is not known.HIV incidence/100 PY with a minimum follow-up of 48 weeks and at least 50% of patients having 96 weeks of follow-up. HIV-1–negative status must be confirmed immediately prior to initiation. https://www.webmd.com/drugs/2/drug-171500/descovy-oral/details Available for Android and iOS devices. Get ready-to-use slides on women's health market trends for 2019 and beyond . DESCOVY for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. Pre-exposure prophylaxis (or PrEP) is when people at risk for HIV take daily medicine to lower their chances of getting HIV. Everything is normal, but my provider says I should switch from Truvada to Descovy because it’s less harsh on the kidneys. "FDA approves second drug to prevent HIV infection as part … DESCOVY ® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. Truvada vs. Descovy for HIV prevention. There are no manufacturing concerns or supply shortages with any Gilead products. The trial showed that Descovy was similar to Truvada in reducing the risk of acquiring HIV-1 infection.
Descovy for PrEP should be used as part of a comprehensive strategy, including adherence to daily administration and safer sex practices, including condoms, to reduce the risk of sexually acquired infections.The safety and efficacy of Descovy for PrEP were evaluated in a randomized, double-blind multinational trial in 5,387 HIV-negative men and transgender women who have sex with men and were at risk of HIV-1 infection. Descovy PrEP FDA Approval: U.S. Food and Drug Administration. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries. DESCOVY for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. We are profoundly grateful for your dedication to helping patients and communities affected by COVID-19. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.